Yale Medicine Urology | Association Partnerships

Latest from Yale Medicine Urology


Dr. Petrylak highlights the latest advances in metastatic urothelial cancer

March 22, 2022

In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.